COVID-19: Boehringer Ingelheim Commits USD 500,000 to American Thoracic Society’s COVID-19 Fund
Boehringer Ingelheim’s support will help the American Thoracic Society (ATS) fight COVID-19 and assist the pulmonology community’s most urgent research, educational and scientific needs
Boehringer Ingelheim is committing USD 500,000 (around EUR 458,000) to the American Thoracic Society (ATS) and its COVID-19 Crisis Fund. Boehringer Ingelheim is the first donor to this important fund to help healthcare professionals on the frontlines of the outbreak. Our support will help ATS’s wide-reaching efforts to fight COVID-19 and assist the pulmonology and critical care communities. The fund will focus on several areas, including the development and dissemination of research, education and scientific recommendations to providers in the pulmonary and critical care communities, as well as other clinicians in need of expanding their skill set during this emergency.
